All posts by imreal

Arcview Market Research and BDSA Agree the Declaration of Cannabis as an ‘Essential Service’ Amid COVID-19 Pandemic Is Historic Moment


DECLARATION OF CANNABIS AS AN ‘ESSENTIAL SERVICE’ AMID COVID-19 PANDEMIC IS HISTORIC MOMENT

DECLARATION OF CANNABIS AS AN ‘ESSENTIAL SERVICE’ AMID COVID-19 PANDEMIC IS HISTORIC MOMENT

The fundamental fact underlying the forecast of worldwide growth to $46.8 billion in 2025 is simple: even at $14.8 billion in 2019, legal spending represented just a sliver of global cannabis spending, including the illicit trade

Arcview Market Research and BDSA (formerly BDS Analytics) forecast worldwide legal cannabis industry revenue will grow another 38% to $20.4 billion in 2020. The eighth edition of the widely-cited “State of Legal Cannabis Markets” series also forecasts sales to reach $46.8 billion in 2025, growing at a 21.2% compound annual growth rate (CAGR) from 2019-2025.

Cannabis has been designated an “essential service” by state governments amid COVID-19 restrictions within cannabis-friendly U.S. states, demonstrating the dramatic change of status for cannabis over the last decade. Most notably, the designation enables government and industry to work together effectively towards a common goal of improving the economy and providing critical access to medical and wellness products. As quarantines lift, support from state officials looking to fill budget shortfalls from the recession could result in more legalization efforts.

“The shelter-in-place orders that began in mid-March could prompt cash-starved state governments to accelerate legalization in a bid for tax revenue,” said Troy Dayton, founder and Chief Strategy Officer of The Arcview Group. “Despite several states postponing planned 2020 legalization ballot measures due to COVID-19, the current forecast shows all Americans having access to medical cannabis by 2025.”

The global legal cannabis industry CAGR of 34.3% (between 2013 and 2019) can be mostly attributed to shifting views and baseline demand. Looking ahead, the worldwide market is expected to more than triple- from $14.8 billion in 2019 to $46.8 billion- in 2025. The top contributors to U.S. growth will include California, Florida, New York, Illinois, and New Jersey.

“The fundamental fact underlying the forecast of worldwide growth to $46.8 billion in 2025 is simple: even at $14.8 billion in 2019, legal spending represented just a sliver of global cannabis spending, including the illicit trade,” said Roy Bingham, Executive Chairman at BDSA.

Other key trends analyzed in the State of the Legal Cannabis Markets, Eighth Edition, include:


  • Several key features of the U.S. market that will support a CAGR of 18.2% to $33.9 billion in 2025.
  • The implications for companies and investors as publicly traded cannabis companies transition from “story stocks” to equities that trade on fundamental analysis and management execution.
  • Canada’s combined medical and adult-use spending nearly tripled from $582 million to $1.6 billion in 2019. Revenue is forecast to grow 73% to $2.8 billion in 2020 due to growing store counts in populous provinces, plus the late-2019 allowance of new product types.
  • Germany constitutes 22% of overseas sales with its medical-only program. With most countries limiting legalization to medical cannabis, the major driver of spending for the forecast period will be Mexico’s anticipated legalization of adult use (both medical and recreational). Mexico and Germany are on-track to account for 40% of 2025 international sales, excluding the U.S. and Canada.

Through seven annual editions, The State of Legal Cannabis Markets has been the definitive report on the worldwide legal cannabis industry. Since the fifth edition, the report has been produced by Arcview Market Research in partnership with BDSA, bringing BDSA’s unique retail-sales tracking and consumer studies to the forecasting of legal cannabis spending in over 50 US states and territories, ten Canadian provinces and territories and 40 countries.

Order the full report of Arcview Market Research’s The State of Legal Cannabis Markets 8th Edition to get the latest cannabis industry data and give your company a dealmaking edge as you navigate the ever evolving cannabis industry https://research.arcviewgroup.com/solcm8/.

About The Arcview Group

The Arcview Group blazed the trail for cannabis investments and is the largest and 1st vertically integrated firm servicing the industry. As a trusted global leader and nexus for investors, companies, entrepreneurs, money-managers and community, Arcview provides an expansive ecosystem that delivers a broad spectrum of programs and services to the industry. Arcview is synonymous with best-in-class. By providing the tools necessary and curating top-notch cannabis companies, Investor Members have had the playbook that has enabled them to invest hundreds of millions in more than 300 private cannabis startups. Furthermore, Arcview Market Research is the #1 source cited for market data, thought leadership and insights. In early 2020, Arcview Ventures was launched, as a member-managed fund that pools resources and strategic alliances together to make collective investment decisions. Arcview continues to expand novel programs, proprietary technology and platforms and international footprint. For more information, please visit https://arcviewgroup.com/

About BDSA

Headquartered in Boulder, CO, BDSA (formerly BDS Analytics) helps businesses improve revenues, reduce innovation risk and prioritize market expansion. The company provides a holistic understanding of the cannabinoid market by generating comprehensive, accurate and actionable insights across point-of-sale data, consumer research and global forecast models, available through the award-winning GreenEdge® data platform. To learn how you can utilize BDSA’s market research and insights, visit http://www.bdsa.com.

Share article on social media or email:

The 20 MSP Achieves HIPAA Compliance with Compliancy Group


HIPAA Compliance Verification Seal of Compliance

“We are all very excited to have completed the thorough process of becoming HIPAA compliant,” said Tim Conkle, CEO of The 20, “Our partnership with Compliancy Group will greatly benefit our MSP members and end clients.”

The 20 is pleased to announce that it has taken all necessary steps to prove its good faith effort to achieve compliance with the Health Insurance Portability and Accountability Act (HIPAA). Through the use of Compliancy Group’s proprietary HIPAA solution, The GuardTM The 20 can track their compliance program and has earned their Seal of ComplianceTM. The Seal of Compliance is issued to organizations that have implemented an effective HIPAA compliance program through the use of The Guard.

HIPAA is made up of a set of regulatory standards governing the security, privacy, and integrity of sensitive healthcare data called protected health information (PHI). PHI is any individually identifiable healthcare-related information. If vendors who service healthcare clients come into contact with PHI in any way, those vendors must be HIPAA compliant.

The 20 has completed Compliancy Group’s Implementation Program, adhering to the necessary regulatory standards outlined in the HIPAA Privacy Rule, Security Rule, Breach Notification Rule, Omnibus Rule, and HITECH. Compliancy Group has verified The 20’s good faith effort to achieve HIPAA compliance through The Guard.

“We are all very excited to have completed the thorough process of becoming HIPAA compliant,” said Tim Conkle, CEO of The 20, “Our partnership with Compliancy Group will greatly benefit our MSP members and end clients. We will ensure that both their business and IT practices are adhering to HIPAA regulations and standards.”

Clients and patients are becoming more aware of HIPAA compliance requirements and how the regulation protects their personal information. Forward-thinking providers like The 20 choose the Seal of Compliance to differentiate their services.

About The 20:

The 20 is an exclusive business development group for Managed Service Providers (MSP) aimed at dominating and revolutionizing the IT industry with its standardized all-in-one approach. The 20’s robust RMM, PSA, and documentation platform ensures superior service for its MSPs’ clients utilizing their completely US-based Help Desk and Network Operations Center. Extending beyond world-class tools and processes, The 20 touts a proven sales model, a community of industry-leaders, and ultimate scalability. For more information, visit https://www.the20.com.

Follow The 20: Twitter, LinkedIn and Facebook

About Compliancy Group:

HIPAA should be simple. That’s why Compliancy Group is the only HIPAA software with expert Compliance CoachesTM holding your hand to simplify compliance. Built by auditors, Compliancy Group gives you confidence in your compliance plan to reduce risk, increase patient loyalty, and profitability of your organization. Visit https://www.compliancy-group.com or call 855.854.4722 to learn how simple compliance can be.

Verify our Seal of Compliance!

Share article on social media or email:



US BioTek Laboratories Launches COVID-19 Testing Services


US BioTek Laboratories, a CLIA (Clinical Laboratory Improvement Amendments) accredited laboratory, announces that it has expanded its capabilities to include coronavirus testing. Best known as a provider of immunology profiles used to identify food and airborne allergies and sensitivities, US BioTek performs FDA EUA authorized diagnostic (RT-PCR) and antibody tests for COVID-19 at its Shoreline, WA facility. Available for use by licensed healthcare providers, the addition of COVID-19 testing comes at a time when many US labs are reaching or near capacity, resulting in long wait times for patient results. US BioTek can serve as an additional COVID-19 testing resource anywhere in the country and help healthcare providers accelerate the process for their patients, with turnaround times of typically 24-48 hours including shipping.

“As the magnitude of COVID-19 became apparent, we recognized that we had a unique capability to provide much needed testing,” said Jack Frausing, CEO of US BioTek Laboratories. “We have a modern, state-of-the-art lab and trained staff already in place, so adding this much-needed service was an easy decision. We are pleased to be able to do our part in the fight against the virus.”

US BioTek’s COVID-19 Diagnostic Test has received FDA EUA authorization (https://www.fda.gov/media/137922/download) and is performed on a Thermo Fisher system using real-time reverse polymerase chain reaction (RT-PCR) technology to detect the presence of the SARS-CoV-2 virus in a patient, the current standard for identifying infected individuals. The test is performed using a sample collected from a patient by nasopharyngeal, oropharyngeal, nasal mid-turbinate, or anterior nasal swab. Additional collection methods are currently under review and will be supported by US BioTek once approved for use by the FDA.

US BioTek also offers a serological test to detect antibodies to the virus. This test has also received FDA EUA (https://www.fda.gov/media/138071/download) and is performed on a high sensitivity electro chemiluminescent platform developed by Roche, and the test may help to identify prior exposure to the SARS-CoV-2 virus. It can also be used to confirm a COVID-19 test result performed on a PCR system, particularly when a false-negative result is suspected due to inadequate sample collection.

More information on both tests can be found on US BioTek Laboratories’ website at https://www.usbiotek.com/covid-19-tests.

About US BioTek Laboratories

US BioTek Laboratories, Inc. is a Clinical Laboratory Improvement Amendments (CLIA) accredited testing facility headquartered north of Seattle in Shoreline, Washington. With over 30 years’ experience in enzyme-linked immunosorbent assay technology, it employs the latest laboratory science, advanced automation technology, and a dedicated research team to ensure the accuracy and reproducibility of each test it performs. More information is available at http://www.usbiotek.com.

US BioTek Laboratories has received approval from the Washington State Department of Health to perform COVID-19 RT-PCR and antibody tests (https://www.usbiotek.com/hubfs/Licenses%20and%20Certificates/US%20BioTek%20COVID-19%20WA%20DOH%20Approval.pdf). As stated in Section IV.B of the FDA’s Policy for Coronavirus Disease-2019 Tests, a State or territory choosing to authorize laboratories within that State or territory to develop and perform a test for COVID-19 would do so under authority of its own State law, and under a process that it establishes. As noted in the guidance, FDA does not intend to object to the use of such tests for specimen testing where the notification of SARS-CoV-2 test validation is not submitted to FDA and the laboratory does not submit an EUA request to FDA, and where instead the State or territory takes responsibility for COVID-19 testing by laboratories in its State/territory during the COVID-19 outbreak. The Washington State Department of Health has notified FDA that they choose to use this flexibility to expedite COVID-19 testing.

Share article on social media or email:

County Line Chiropractic is Proud to Open a New Location in East Fort Lauderdale


County Line Chiropractic opens 6th new location in East Fort Lauderdale

County Line Chiropractic has opened a new location in East Fort Lauderdale.

Car accident victims have a new place to turn when seeking treatment for ongoing aches and pains, now that County Line Chiropractic has opened a new location in East Fort Lauderdale.

County Line Chiropractic specializes in helping car accident victims deal with their injuries in a holistic manner that doesn’t involve pain medication or invasive treatments and procedures. Instead, they believe that a customized treatment plan should dive into the root cause of the pain. Now with six convenient locations, it is easier than ever for patients with new or chronic pain to seek treatment.

The new East Fort Lauderdale location at 926 East Cypress Creek Road in Fort Lauderdale, Florida, offers several versatile treatment options and diagnostic tests. Run by Dr. Laura Hochstein, formerly of the Miami Gardens location, patients can receive ultrasound therapy, hands-on chiropractic treatments, and physical rehabilitation in a private treatment room. Patients can schedule an appointment over the phone or online, and walk-ins are also welcome. Transportation for auto accident victims will also be offered at the East Fort Lauderdale location.

Dr. Laura Hochstein is a Broward County Native who has a Bachelor of Science degree in Biology, as well as a Doctorate in Chiropractic Medicine. She was inspired to become a chiropractor after growing up watching her father, Dr. Robert Hochstein, help patients pinpoint the underlying causes of their pain. Now, she continues the legacy from the new County Line Chiropractic office in East Fort Lauderdale.

For more information about the new East Fort Lauderdale location, visit the County Line Chiropractic website.

More About County Line Chiropractic

At County Line Chiropractic, our mission is to help our patients find pain relief through natural recovery. Our experienced chiropractors are determined to find the source of your injury and design a customized care plan to heal your body effectively and naturally to reduce long-term or chronic pain. We have been serving the residents of Miami Gardens, North Miami Beach, Plantation, Pembroke Pines, and Lauderhill in Florida since 1986 and are ready to help you.

We offer chiropractic care to anyone suffering from chronic pain or muscle aches and pains, as well as victims of work or auto injuries. Whatever your pain stems from, we will help find the cause and offer relief. Our chiropractors in the Broward and Miami-Dade counties help develop customized, non-invasive plans for long-term chiropractic care. For more information, please visit the County Line Chiropractic website (http://www.countylinechiro.com) or call 800-811-1231.

Share article on social media or email:

Eriksen Translations Releases COVID-19 Glossary in 18 Languages


Eriksen Translations

To combat this pandemic, everyone needs information in a language they can understand. By creating this glossary, we are doing our part to protect the health and well-being of our communities.

Eriksen Translations, a leading language services provider, has published a glossary of 150 COVID-19 terms in 18 languages. This resource has been made available at no charge to support healthcare organizations and government agencies, as well as the general public, in keeping people safe and informed during the pandemic.

LANGUAGE ACCESS DURING THE PANDEMIC

The COVID-19 health crisis makes language more important than ever. From handwashing to social distancing, the appropriate precautions can limit the spread of the virus. This means information about the pandemic and all pertinent public health guidelines must be made available in as many languages as is feasible. Consequently, translators have become crucial for their role in making critical health information accessible to individuals with limited English proficiency.

HOW GLOSSARIES SUPPORT ACCURATE, CONSISTENT MESSAGING

Eriksen’s COVID-19 glossary is a list of words and phrases that frequently appear in communications related to the coronavirus pandemic. Each term is translated into 18 languages: Arabic, Bengali, Chinese-Simplified, Chinese-Traditional, French, Greek, Haitian Creole, Hebrew, Hindi, Italian, Japanese, Korean, Portuguese, Polish, Russian, Spanish, Urdu, and Yiddish.

To translate and edit the glossaries, Eriksen carefully assembled a team of 36 medical translators, doctors, and biomedical researchers. Each team was highly skilled in its target language, with collective experience translating public health-related subject matter and medical terminology.

As the pandemic continues, language barriers should not stand between people and the information they need to keep themselves and their families safe. As healthcare providers, local governments, and community organizations communicate across languages, a glossary improves the impact of the messaging, giving more people access to reliable, actionable information.

“To combat this pandemic, everyone needs information in a language they can understand,” said Vigdis Eriksen, Founder and CEO of Eriksen Translations. “By creating this glossary, we are doing our part to protect the health and well-being of our communities.”

DOWNLOAD THE GLOSSARY

Each language can be downloaded in PDF format:

Arabic | Bengali | Chinese-Simplified | Chinese-Traditional | French | Greek | Haitian Creole | Hebrew | Hindi | Italian | Japanese | Korean | Polish | Portuguese | Russian | Spanish | Urdu | Yiddish

You can also download all languages in Excel.

Please visit https://www.eriksen.com/general/translation-importance-during-covid19/ to read more.

ABOUT ERIKSEN TRANSLATIONS

Eriksen Translations delivers best-in-class multilingual services in 100+ languages. Founded in downtown Brooklyn in 1986, Eriksen offers translation, typesetting, web and multimedia localization, transcreation, transcription, voiceover and subtitling, live Zoom captioning, and interpreting services to clients worldwide. Throughout the pandemic, Eriksen has provided government agencies, hospitals, cultural organizations, and other partners with the language services they need to make COVID-19 communications accessible to individuals with limited English proficiency.

Eriksen is certified as a woman-owned business enterprise (WBE) by the Women’s Business Enterprise National Council (WBENC) and the City and State of New York. For more information, visit http://www.eriksen.com / @eriksentrans

Share article on social media or email:

DIIMSA Guidesets have helped educators maintain continuous instruction during the Pandemic


When it comes to Digital Generation Learners, it takes vision, research and innovation to create empowering activities and strategies. To reach this generation during the COVID-19 Pandemic, DIIMSA Researchers have developed an empowering real world connection activity for in-person, remote, virtual or hybrid instructional plans — DIIMSA Pics-Fair.

In this digital age, how do educators teach children who appear to know more about technology than adults do? How do educators help socially or economically disadvantaged students achieve in science? How do educators train and motivate teachers to integrate science and literacy into the curriculum during the COVID-19 Pandemic? Educating students born surrounded by technology and digital media provides great challenges for educators and adding the constraints of the COVID-19 Pandemic makes it more challenging. Teachers are finding it difficult to use problem solving and inquiry to get students interested in the details of science. Even teachers with the best of skills can find themselves behind the curve in providing relevancy and competence in their instructional plans. Many educators consider technology a potent vehicle for transforming education, yet only a few report any confidence in integrating true technology into classroom instruction as schools move into options for learning. DIIMSA Pics-Fair (Digital Imagery as an Instructional Mode for Student Achievement Picture Fair) addresses these issues by providing techniques to engage, stimulate and motivate learners to want to learn topics, concepts, vocabulary and content. DIIMSA Pics-Fair provides a way for educators to enhance instructional plans for in-person, remote, virtual or hybrid instruction by providing techniques to engage, stimulate and motivate learners to want to learn topics, concepts, vocabulary and content.

DIIMSA Pics-Fair is a topic- or concept-to-picture Instructional Assignment that provides a way for students to let the camera drive the content as they explore and research science in their own communities. The primary goal of DIIMSA Pics-Fair is to allow students to make connections to their learning in a different context by using authentic images captured by students themselves. Students will learn how to analyze and research their selected topic or concept by using a dynamically-captured digital image that directly relates to it. DIIMSA Pics-Fair provides an innovative approach for teachers and facilitators to integrate science and literacy as they guide learners to produce works that are supported with a clear, concise summary, supporting vocabulary, linked concepts and a related hypothesis.

DIIMSA Pics-Fair guidesets include research-based activities that provide a roadmap for teachers. Guidesets provide everything educators need to get started. DIIMSA facilitators, teachers and administrators use these guidesets to stimulate students’ interest and involvement in science. Guidesets are aligned to science concepts that are taught across all 50 states and linkages to the Next Generation Science Standards.

In addition to guidesets, DIIMSA researchers have expanded approaches for educators to advance and gain access to DIIMSA Stock to help support activities in the guidesets. DIIMSA Stock is a unique stock imagery site that has a diverse set of high-resolution imagery across corporate, industrial and academic spaces. All images and video clips have a connection to the why behind the scenes and are natural and authentic. All scenes on these sites were captured by DIIMSA Researchers and are available for inclusion in instructional plans.

Join us in announcing the DIIMSA Pics-Fair Guidesets for options during the COVID-19 Pandemic. Learn more by visiting the DIIMSA learning community resources.

About Visualrealization.com

Established in 2000, Visualrealization.com is a practice-based professional development program for teachers. Visualrealization.com uses its research-based DIIMSA Model to improve teacher quality and increase student engagement leading to student achievement. DIIMSA was developed by VisualRealization.com’s educational leadership team to provide teachers with the skills and resources needed to maintain students’ interest in science and bolster their academic achievement. DIIMSA synergistically integrates Conceptual Teaching, Collaborative Learning and Enabling Technologies in classroom teaching that can be demonstrated as students engage in campus-based, field excursion, laboratory and case study experiences.

Share article on social media or email:

O’Neill Innovations Agrees Exclusive Distribution Sales Agreement with Realy Tech Covid-19 Antibody Test Kits


Covid 19 Rapid Test

Easy to use and interpret results

We can distribute 90,000 test kits in a football stadium and have everyone tested in 10 minutes.

O’Neill Innovations today announced that it has successfully negotiated a contract with Hangzhou Realy Tech Co Ltd to act as Realy Tech’s exclusive representative for sales of its SARS-CoV-2 Antibody test kits in the USA. The deal was completed in mid-March 2020 but is only being announced now as marketing ramps up for the test kits.

As part of the agreement, all product sales will be handled by O’Neill in the USA and it is anticipated that O’Neill will set up a distribution network that guarantees competitive pricing, clear territory assignment, quality control and compliance.

The new test kits have the capability to provide results for the presence of SARS-CoV-2 antibodies in human blood within 2 to 10 minutes. Unlike PCR tests that are prevalent in the market today, these test kits are a fraction of the cost, highly accurate and can be manufactured in high capacity.

The antibody tests do not require any complicated laboratory equipment or chemical reagents. They are not subject to the erroneous errors that occur with PCR sampling techniques and can be easily distributed for point of care testing at any location.

“Testing, testing, testing! We can distribute 90,000 test kits in a football stadium and have everyone tested in 10 minutes. The potential of this technology needs to be released to the public as soon as possible,” said Michael O’Neill, CEO of O’Neill Innovations.

These test kits are regulated by the FDA and can only be used in a “Point of Care” facility with the guidance of a medical professional.

O’Neill Innovations products are highly differentiated and technology driven. They provide benefits that are simple to understand and performance that is easily understood.

O’Neill has curated the Hangzhou Realy Tech’s Covid-19 Rapid Test because it aligns with this criterion for success.

For more information about these Covid-19 Antibody test please email Sales@RealyTech.us or visit http://www.RealyTech.us to join our distribution network.

Share article on social media or email:

NeoTract Designates Dr. Seth Capello as UroLift® Center of Excellence


News Image

“We are proud to name Dr. Seth Capello as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Seth Capello, M.D., Saratoga Hospital Medical Group in Saratoga Springs, NY, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Capello has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Seth Capello as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Competition Heats Up In Molecular Tuberculosis Market According to Kalorama Information


Kalorama Information logo

Molecular diagnostics can be useful in the diagnosis of tuberculosis (TB). The disease is one of the top 10 causes of death worldwide, and molecular’s diagnostic accuracy can assist in ensuring that patients are properly treated and isolated. The field has increased in competitors, as molecular diagnostic systems replace immunoassays.

According to WHO statistics, 10 million people fell ill with TB in 2017 and 1.6 million died from the disease. HIV positive people are susceptible to TB, which is a leading cause of death among them. Multi drug-resistant (MDR) TB is major crisis and as per WHO estimates, 558,000 new TB cases are resistant to rifampicin, the most effective first-line drug and 82% of these patients had MDR-TB. However, TB incidence is falling at a rate of 2% per annum. Around 54 million lives were saved through TB diagnosis and treatment between 2000 and 2017.

COVID-19 has to some degree affected diagnosis and treatment of all other diseases, and tuberculosis is no exception. While experience on COVID-19 infection in tuberculosis (TB) patients remains limited, it is anticipated that people ill with both TB and COVID-19 may have poorer treatment outcomes, especially if TB treatment is interrupted. Older age, diabetes and chronic obstructive pulmonary disease (COPD) are linked with more severe COVID-19 and are also risk factors for poor outcomes in TB. COVID-19 transmission has primarily been attributed to the direct breathing of droplets expelled by someone with COVID-19.

The key player in the market is Cepheid’s GeneXpert system and its Xpert MTB/RIF assay for the detection of TB and rifampicin resistance in sputum samples. The use of this rapid test has expanded across the world substantially since 2010 after WHO recommended its use. The test simultaneously detects TB and resistance to rifampicin, the most important TB medicine. Diagnosis can be made within 2 hours and the test is recommended by WHO as the initial diagnostic test in all persons with signs and symptoms of TB.

There are competitors. May 2019 Roche announced the CE-IVD marking of its Cobas MTB-RIF/INH test that detects mutations associated with resistance to the antibiotics rifampicin and isoniazid within tuberculosis DNA. The assay is part of Roche’s mycobacteria test menu that runs on its Cobas 6800/8800 automated molecular platforms and also includes the Cobas MTB and Cobas MAI tests. In 2019, Roche announced that it would increase its Global Access Program beyond HIV diagnostics. The program is a partnership with national governments, local healthcare facilities, communities and international agencies to establish programs and increased access to diagnostics at affordable pricing for qualifying organizations in eligible countries with the highest disease burden.

Another competitor is Qiagen. February 2020, Qiagen announced that its QuantiFeron-TB Gold Plus (QFT-Plus) blood test for detecting latent tuberculosis (TB) has been recommended in national screening guidelines from Nigeria’s health ministry. Nigeria is the first high-burden country to exclusively embrace interferon gamma release assays (IGRAs) for latent TB screening of at-risk individuals in tuberculosis control programs, Qiagen noted. The national guidelines are based on World Health Organization (WHO) recommendations for screening, and including IGRA tests will help avoid progression to active TB,

Tuberculosis molecular testing will be covered in Kalorama Information’s upcoming report on the topic. Kalorama Information publishes market studies at http://www.kaloramainformation.com.

Share article on social media or email:

Premier Mortgage Resources, LLC, launches ‘Hometown Heroes’ program


Premier Mortgage Resources, LLC

“As a lender, we are in a unique position that allows us to directly ease the financial burden that so many are experiencing right now and, most importantly, we want to express our deep gratitude,” said PMR Managing Partner Cory Swain.

As a gesture of gratitude to local public safety professionals working on the front lines of the COVID-19 pandemic, Premier Mortgage Resources, LLC, has launched a new home loan savings program, called “Hometown Heroes.”

Under this program, any first responder or health care professional approved for a home loan through PMR will receive a closing cost credit. Qualifying borrowers are eligible for a credit of up to $1,295 toward the cost of closing their home loan from a waived documentation fee. If borrowers choose to work with a real estate agent who is participating in the program, they will receive an additional credit amount, determined by the agent.    

“As a lender, we are in a unique position that allows us to directly ease the financial burden that so many are experiencing right now and, most importantly, we want to express our deep gratitude,” said PMR Managing Partner, Cory Swain. “It’s such a privilege to be able to show our thanks to local heroes who are doing so much for the communities we lend in. We are truly in awe of the work they are doing.”

In addition to offering the program’s discount, loan officers are prepared to help health care professionals navigate the home loan process during this uncertain time. Homeowners are encouraged to contact a local branch to be put in touch with a loan officer who can assist with their unique financial situation.

“We know that the sacrifices being made by health care professionals are immeasurable, and we want to remove any barriers to homeownership that they may be experiencing so that they can focus on what matters most; the health and safety of themselves, their families and community members,” said Producing Branch Manager, Mandi Feely.

About Premier Mortgage Resources, LLC

PMR has been helping homebuyers achieve the dream of homeownership since 1991 and has grown to 31 branches throughout the United States, with a team of more than 120 loan officers ready to assist homebuyers in achieving their financial goals. The company prides itself on excellence in customer service, competitive rates and the best mortgage programs available. For more information about the Hometown Heroes program, visit PMRLoans.com.

Share article on social media or email: